Juvaris Biotherapeutics, Inc.
Records under this name other than the patents Juvaris Biotherapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Juvaris Biotherapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,044,215 | Methods for the Preparation of Amphillic Nitrogen Containing Imidazolinium Derivative Compounds Lapsed on the fee record Ended Oct 25, 2023 · High confidence | Lapsed on the fee record | Ended Oct 25, 2023 | High confidence |
| US 8,945,590 | Enhancement of an Immune Response by Administration of a Cationic Lipid-DNA Complex (CLDC) Lapsed on the fee record Ended Feb 3, 2023 · High confidence | Lapsed on the fee record | Ended Feb 3, 2023 | High confidence |
| US 6,344,446 | Cationic lipid:DNA complexes for gene targeting Term ended Ended no later than Jun 7, 2015 · USPTO record | Term ended | Ended no later than Jun 7, 2015 | USPTO record |
| US 5,705,655 | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses Term ended Term ended no later than Jan 6, 2018 · Low confidence | Term ended | Term ended no later than Jan 6, 2018 | Low confidence |
| US 5,736,395 | Amphiphilic imidazolinium derivatives Term ended Term ended no later than Apr 7, 2018 · Low confidence | Term ended | Term ended no later than Apr 7, 2018 | Low confidence |
| US 5,830,878 | Cationic lipid: DNA complexes for gene targeting Term ended Term ended no later than Nov 3, 2018 · Low confidence | Term ended | Term ended no later than Nov 3, 2018 | Low confidence |